193 related articles for article (PubMed ID: 26853852)
1. Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target.
Burgler S
Crit Rev Immunol; 2015; 35(5):417-32. PubMed ID: 26853852
[TBL] [Abstract][Full Text] [Related]
2. Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia.
Vaisitti T; Audrito V; Serra S; Bologna C; Arruga F; Brusa D; Buonincontri R; Gizdic B; Deaglio S
Curr Top Med Chem; 2013; 13(23):2955-64. PubMed ID: 24171772
[TBL] [Abstract][Full Text] [Related]
3. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.
Brachtl G; Piñón Hofbauer J; Greil R; Hartmann TN
Ann Hematol; 2014 Mar; 93(3):361-74. PubMed ID: 24288111
[TBL] [Abstract][Full Text] [Related]
4. CD38 and chronic lymphocytic leukemia: a decade later.
Malavasi F; Deaglio S; Damle R; Cutrona G; Ferrarini M; Chiorazzi N
Blood; 2011 Sep; 118(13):3470-8. PubMed ID: 21765022
[TBL] [Abstract][Full Text] [Related]
5. THE PROGNOSTIC SIGNIFICANCE OF COMBAIND EXPRESSION OF ZAP-70 AND CD38 IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Kirtava T; Vatsadze T; Azrmaiparashili E; Ghirdaladze D
Georgian Med News; 2017 Jun; (267):12-16. PubMed ID: 28726646
[TBL] [Abstract][Full Text] [Related]
6. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.
Deaglio S; Vaisitti T; Aydin S; Bergui L; D'Arena G; Bonello L; Omedé P; Scatolini M; Jaksic O; Chiorino G; Efremov D; Malavasi F
Blood; 2007 Dec; 110(12):4012-21. PubMed ID: 17699742
[TBL] [Abstract][Full Text] [Related]
7. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.
Deaglio S; Vaisitti T; Aydin S; Ferrero E; Malavasi F
Blood; 2006 Aug; 108(4):1135-44. PubMed ID: 16621959
[TBL] [Abstract][Full Text] [Related]
8. CD38 as a multifaceted immunotherapeutic target in CLL.
Paulus A; Malavasi F; Chanan-Khan A
Leuk Lymphoma; 2022 Oct; 63(10):2265-2275. PubMed ID: 35975791
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
10. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Gooden CE; Jones P; Bates R; Shallenberger WM; Surti U; Swerdlow SH; Roth CG
Cytometry B Clin Cytom; 2018 Jan; 94(1):129-135. PubMed ID: 27221715
[TBL] [Abstract][Full Text] [Related]
11. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.
Vaisitti T; Audrito V; Serra S; Buonincontri R; Sociali G; Mannino E; Pagnani A; Zucchetto A; Tissino E; Vitale C; Coscia M; Usai C; Pepper C; Gattei V; Bruzzone S; Deaglio S
Leukemia; 2015 Feb; 29(2):356-68. PubMed ID: 24990614
[TBL] [Abstract][Full Text] [Related]
12. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia.
Tonino SH; Spijker R; Luijks DM; van Oers MH; Kater AP
Blood; 2008 Aug; 112(3):840-3. PubMed ID: 18519815
[TBL] [Abstract][Full Text] [Related]
13. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
[No Abstract] [Full Text] [Related]
14. CD38 in chronic lymphocytic leukemia: from bench to bedside?
Deaglio S; Vaisitti T; Serra S; Audrito V; Bologna C; D'Arena G; Laurenti L; Gottardi D; Malavasi F
Mini Rev Med Chem; 2011 Jun; 11(6):503-7. PubMed ID: 21561406
[TBL] [Abstract][Full Text] [Related]
15. Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.
Brachtl G; Sahakyan K; Denk U; Girbl T; Alinger B; Hofbauer SW; Neureiter D; Hofbauer JP; Egle A; Greil R; Hartmann TN
PLoS One; 2011; 6(8):e23758. PubMed ID: 21876768
[TBL] [Abstract][Full Text] [Related]
16. Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF).
Dignum HM; Summerfield GP; Proctor SJ; Mainou-Fowler T
Leuk Lymphoma; 2004 Jun; 45(6):1167-73. PubMed ID: 15359996
[TBL] [Abstract][Full Text] [Related]
17. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.
Deaglio S; Capobianco A; Bergui L; Dürig J; Morabito F; Dührsen U; Malavasi F
Blood; 2003 Sep; 102(6):2146-55. PubMed ID: 12763926
[TBL] [Abstract][Full Text] [Related]
18. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia.
D'Arena G; Musto P; Cascavilla N; Dell'Olio M; Di Renzo N; Perla G; Savino L; Carotenuto M
Leuk Lymphoma; 2001 Jun; 42(1-2):109-14. PubMed ID: 11699197
[TBL] [Abstract][Full Text] [Related]
19. The CD38 ectoenzyme family: advances in basic science and clinical practice.
Morabito F; Damle RN; Deaglio S; Keating M; Ferrarini M; Chiorazzi N
Mol Med; 2006; 12(11-12):342-4. PubMed ID: 17380202
[TBL] [Abstract][Full Text] [Related]
20. CD38 and bone marrow microenvironment.
Chillemi A; Zaccarello G; Quarona V; Lazzaretti M; Martella E; Giuliani N; Ferracini R; Pistoia V; Horenstein AL; Malavasi F
Front Biosci (Landmark Ed); 2014 Jan; 19(1):152-62. PubMed ID: 24389178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
